References for Program Overview

  1. Tsigelny IF, Bar-On P, Sharikov Y, Crews L, Hashimoto M, Miller MA, Keller SH, Platoshyn O, Yuan JX, Masliah E (2007) Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. FEBS J. 274(7):1862-77.
  2. Tsigelny IF, Sharikov Y, Miller MA, Masliah E (2008) Mechanism of alpha-synuclein oligomerization and membrane interaction: theoretical approach to unstructured protein studies. Nanomedicine. 4(4):350-7.
  3. Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, Spencer B, Rockenstein E, Trejo M, Platoshyn O, Yuan JX, Masliah E (2008) Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS One. 3(9):e3135.
  4. Tsigelny IF, Sharikov Y, Wrasidlo W, Gonzalez T, Desplats PA, Crews L, Spencer B, Masliah E (2012) Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation. FEBS J. 279(6):1000-13.
  5. Duda J, Giasson BI, Mabon ME, Miller DC, Golbe L, Lee VM-Y, Trojanowski JQ (2002) Concurrence of α-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathology , 104 :7–11.
  6. Ikeuchi T, Kakita A, Shiga, A; Kasuga K, Kaneko H, Tan C-F, Idezuka, J, Wakabayashi K, Onodera O, Iwatsubo T, Nishizawa M, Takahashi H, Ishikawa A (2008) Patients Homozygous and Heterozygous for SNCA Duplication in a Family With Parkinsonism and Dementia. Arch Neurol. , 65(4):514-519.
  7. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe5 M, Takeda A, Tomiyama H, Nakashima K, Hasegawa K, Obata F, Yoshikawa T, Kawakami H, Sakoda S, Yamamoto M, Hattori N, Murata M, Nakamura Y, Toda T (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nature Genetics, 41(12): 1303-1307.
  8. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke M (2000) Dopaminergic Loss and Inclusion Body Formation in a-Synuclein Mice: Implications for Neurodegenerative Disorders. Science, 287:1265-1269.
  9. Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, Masliah E (2002) Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res., 68(5):568-78.
  10. Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, Chesselet MF (2004) Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci., 24(42):9434-40.
  11. Price DL, Wrasidlo W, Tsigelny I, Bonhaus D, Paulino AD, Mante M, Inglis C, Adame A, Moessler H, Rockenstein E, Masliah E (2011) Novel structure based designed compound reduces accumulation of toxic alpha-synuclein and improves deficits in a transgenic murine model of PD/DLB. Society for Neuroscience, Abstract 357.25
  12. Koike MA, Price DL, White BM, Rockenstein E, Wrasidlo W, Tsigelny I, Meier D, Masliah E, Bonhaus D (2014) The novel alpha-synuclein stabilizer NPT200-11 improves behavior, neuropathology, and biochemistry in the murine thy1-ASYN transgenic model of Parkinson’s disease. Society for Neuroscience, Abstract 411.06
  13. Wong E, Cuervo AM (2010) Autophagy gone awry in neurodegenerative diseases. Nat Neurosci., 13(7):805-11.
  14. Petersén A, Larsen KE, Behr GG, Romero N, Przedborski S, Brundin P, Sulzer D (2001) Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration. Hum Mol Genet. , 10(12):1243-54.
  15. Beilina A, Cookson MR (2015) Genes associated with Parkinson's disease: regulation of autophagy and beyond. J Neurochem. 
  16. Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA (2001) Expression of A53Tmutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci., 21(24):9549-60.
  17. Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C, Gindi R, Adame A,Wyss-Coray T, Masliah E (2009) Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J Neurosci., 29(43):13578-88.
  18. Chen L, Xie Z, Turkson S, Zhuang X (2015) A53T human α-synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degeneration. J Neurosci., 35(3):890-905.
  19. Crews L, Spencer B, Desplats P, Patrick C, Paulino A, Rockenstein E, Hanson L, Adame A, Galasko D, Masliah E (2010) Selective Molecular Alterations in the Autophagy Pathway in Patients with Lewy Body Disease and in Models of a-Synucleinopathy. PLoS ONE 5(2): e9313.
  20. Larsen KE, Sulzer D (2002) Autophagy in neurons: a review. Histol Histopathol. , 17(3):897-908.